ArtemiFlow

ArtemiFlow is a biotechnology company headquartered in Potsdam, Germany, focused on artemisinin and artemisinin-derivative pharmaceuticals. Artemisinin is a plant-derived antimalarial compound and an important component of artemisinin-based therapies used against malaria. The company was founded in 2012 by chemist Peter Seeberger, whose work centered on making artemisinin available through a more scalable, cost-conscious, and environmentally considerate manufacturing route. The company emerged from efforts to address limitations in conventional artemisinin supply. Artemisinin has historically depended heavily on cultivation of Artemisia annua, also known as annual mugwort or sweet wormwood, followed by extraction and chemical processing. Supply volumes and prices can therefore be affected by agricultural conditions, cultivation decisions, and demand fluctuations. Seeberger's approach sought to combine plant-derived starting materials with an engineered chemical process capable of producing artemisinin in larger quantities. The stated objective was particularly relevant to lower-income and malaria-affected countries, where affordability and supply reliability are central concerns. ArtemiFlow's development path involved substantial technical and commercial obstacles. The company had to translate a laboratory or pilot-scale process into manufacturing at larger scale, establish suitable cultivation of Artemisia annua in Vietnam, and secure financing for a young biotechnology venture. According to the company's first chief executive, Dirk Pohlmann, competition for international malaria funding also made market entry difficult. A separate synthetic-biology route developed by Sanofi, based on genetically modified yeast, received support from major philanthropic funding and represented an established alternative. Moreover, the public announcement of synthetic artemisinin production contributed to lower market prices, reducing incentives for some producers to cultivate the plant. In 2018, ArtemiFlow partnered with the University of Kentucky on cultivation and process research. University researchers grew Artemisia annua in Kentucky, while the company developed a reactor and worked on higher-yielding plants. The collaboration was notable because the process used a plant-derived catalyst as well as plant-derived starting materials, rather than relying only on botanical feedstock for the final chemical route. In 2020, the partners extended their work into a clinical study examining the plant's possible anticancer effects. These activities broadened the company's research interest beyond malaria, although the available reference material does not establish regulatory approval, commercial launch, or clinical efficacy for an oncology product. The underlying process-development work received external recognition in 2021, when Peter Seeberger, Kerry Gilmore, and Andreas Seidel-Morgenstern were awarded the American Chemical Society's Science Prize for Affordable Green Chemistry. As of 2025, Adam Maust is identified as ArtemiFlow's chief executive officer. Publicly available information supplied for this entry does not provide reliable figures for revenue, valuation, production volume, market share, or a complete list of marketed products. It also does not establish a parent company, public listing, or definitive international distribution footprint. ArtemiFlow is therefore best characterized as a specialized biotechnology and pharmaceutical-development company whose brand is closely associated with affordable artemisinin production and plant-based process innovation.

ArtemiFlow was founded in 2012 by Peter Seeberger to pursue a more scalable and economical route for producing artemisinin and related pharmaceutical compounds. The company's work addressed a persistent supply problem in malaria treatment: artemisinin production has traditionally depended on cultivating Artemisia annua and extracting the compound from the plant. Agricultural dependence can create uncertainty in supply, while market-price changes can affect farmers' willingness to grow the crop. Seeberger developed a process intended to produce artemisinin in larger quantities while reducing cost and environmental impact. The approach was positioned as an alternative to Sanofi's genetically engineered yeast process. ArtemiFlow nevertheless faced technical and commercial barriers, including the challenge of scaling the chemistry, cultivating Artemisia annua in Vietnam, and financing the start-up. Dirk Pohlmann, described as the company's first chief executive, also identified the concentration of philanthropic malaria funding around competing products as a difficulty. The prospect of synthetic production itself contributed to lower artemisinin prices, which reduced expected production incentives for some growers. The company expanded its research base through a 2018 partnership with the University of Kentucky. Researchers cultivated Artemisia annua in Kentucky, collaborated on higher-yielding plants, and supported ArtemiFlow's development of a reactor for a new artemisinin-production process. The work was distinctive because the catalyst driving the chemical transformation was also derived from plants. In 2020, the university and company conducted a clinical study related to the plant's possible anticancer effects. The source material does not indicate that this work resulted in a licensed cancer medicine. ArtemiFlow's research was recognized in 2021, when Peter Seeberger, Kerry Gilmore, and Andreas Seidel-Morgenstern received the American Chemical Society's Science Prize for Affordable Green Chemistry. The company also became associated with public debate in 2020 over claims concerning artemisinin and COVID-19. Coverage questioned the evidence for such use and raised possible conflict-of-interest concerns connected with Seeberger's leadership roles. The available material records a critical Süddeutsche Zeitung article and a response published by Focus, but it does not establish a regulatory finding or court judgment against ArtemiFlow. As of 2025, Adam Maust is identified as the company's chief executive officer. Beyond its artemisinin focus and research collaborations, the supplied sources do not provide enough verified information to document a complete commercial product catalog, ownership structure, financial performance, public listing, or geographic sales network.

• 2025

  Adam Maust identified as chief executive

  [1]ArtemiFlowen.wikipedia.org

  Adam Maust was identified as ArtemiFlow's chief executive officer.

• 2021

  Affordable Green Chemistry award

  [1]ArtemiFlowen.wikipedia.org

  Peter Seeberger, Kerry Gilmore, and Andreas Seidel-Morgenstern received the American Chemical Society's Science Prize for Affordable Green Chemistry for their process-development work.

• 2020

  Clinical study related to possible anticancer effects

  [1]ArtemiFlowen.wikipedia.org

  ArtemiFlow and the University of Kentucky partnered on a clinical study examining the plant's potential anticancer effects.

• 2018

  Partnership with the University of Kentucky

  [1]ArtemiFlowen.wikipedia.org

  The company and the university worked on Artemisia annua cultivation, higher-yielding plants, and a reactor for a new artemisinin-production process.

• 2012

  ArtemiFlow was founded

  [1]ArtemiFlowen.wikipedia.org

  Peter Seeberger founded ArtemiFlow to develop scalable and cost-conscious production methods for artemisinin and related pharmaceutical compounds.

A specialized biotechnology company positioned around affordable, scalable, and environmentally considerate production of artemisinin and related pharmaceutical ingredients, with additional research interest in plant-derived compounds and potential anticancer applications.

• Pharmaceuticals

  Artemisinin-containing pharmaceutical products

  ArtemiFlow is described as producing and selling pharmaceutical drugs containing artemisinin. Artemisinin is an important antimalarial active ingredient, although the supplied source does not provide individual product names, formulations, approval jurisdictions, dosage forms, or sales figures.

• Pharmaceuticals

  Artemisinin derivatives

  The company is associated with pharmaceutical drugs containing derivatives of artemisinin. These compounds are discussed in relation to malaria and other diseases, but the available material does not identify a complete commercial portfolio or specific derivative products marketed under the ArtemiFlow name.

• Biotechnology process technology

  Artemisinin production process

  The company's central technology effort is a process designed to manufacture artemisinin in larger quantities with lower cost and environmental impact. Research included a reactor, higher-yielding Artemisia annua plants, and a plant-derived catalyst. The supplied sources do not provide verified manufacturing capacity or commercialization terms.

• 2020

  Controversy over possible COVID-19 use of artemisinin

  Discussion of artemisinin as a possible COVID-19 treatment attracted criticism because of questions about supporting evidence and possible conflicts of interest related to Peter Seeberger's leadership of ArtemiFlow and ArtemiLife. The supplied reference records critical reporting in Süddeutsche Zeitung and a subsequent response in Focus, without documenting a regulatory or judicial determination.

  Source

Read more

• 2020

  Entered clinical research related to possible anticancer effectsOther

  Background

  The University of Kentucky collaboration extended beyond cultivation and chemical production into investigation of possible therapeutic applications.

  Action taken

  ArtemiFlow and the university partnered on a clinical study examining Artemisia annua and potential anticancer effects.

  Aftermath

  The available material does not establish the study's results, regulatory status, or creation of an approved oncology product.

  Source

• 2018

  Expanded cultivation and process-development collaborationStrategy

  Background

  ArtemiFlow needed to improve the supply of plant material and advance its alternative artemisinin-production process.

  Action taken

  The company partnered with the University of Kentucky on Artemisia annua cultivation, higher-yielding plants, and reactor development.

  Aftermath

  The collaboration produced a plant-based process concept and led to further work, including a 2020 clinical study related to potential anticancer effects.

  Source

1. 1ArtemiFlowen.wikipedia.org